Key result
Intravenous administration of the stable prostaglandin I2 analogue ZK 36374 eliminated recurring reductions in coronary blood flow, though it required higher doses than prostaglandin I2.
Why the study?
Does ZK 36374 eliminate recurring reduction of coronary blood flow in a canine model of partially constricted coronary artery compared to prostaglandin I2?
Does ZK 36374 eliminate recurring reduction of coronary blood flow in a canine model of partially constricted coronary artery compared to prostaglandin I2?
p-value: p=<0.05
ZK 36374 is effective in eliminating recurring reduction in coronary flow related to coronary vasospasm and/or thrombosis, although it is weaker than prostaglandin I2.
Supports stable PGI2 analogue testing in canine vasospasm models; leaves open human translation and dosing.
The effects of a stable prostaglandin I2 analogue, ZA 36374, on recurring reduction of blood flow in the partially constricted canine coronary artery were compared with those of prostaglandin I2. Intravenous bolus injections of 0.3 micrograms/Kg ZK 36374 and 0.15 micrograms/Kg prostaglandin I2 eliminated the recurring reductions. Intravenous infusion of 0.1 micrograms/Kg/min ZK 36374 and 0.01 micrograms/Kg/min prostaglandin I2 also eliminated the recurring reductions. The results indicate that although weaker than prostaglandin I2, ZK 36374 is effective in eliminating recurring reduction in coronary flow related to coronary vasospasm and/or thrombosis.
No takes yet. Share an insight, caveat, or question.
Uchida et al. (1983) studied Recurring reduction of coronary blood flow (n=26). ZK 36374 vs. Prostaglandin I2 was evaluated on Elimination of recurring reductions in coronary blood flow (reappearance time) (p=<0.05). Intravenous administration of the stable prostaglandin I2 analogue ZK 36374 eliminated recurring reductions in coronary blood flow, though it required higher doses than prostaglandin I2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: